



Minerva Access is the Institutional Repository of The University of Melbourne

Author/s:

Kinnear, CL;Strugnell, RA

Title:

Vaccination method affects immune response and bacterial growth but not protection in the salmonella typhimurium animal model of typhoid

Date:

2015-10-28

Citation:

Kinnear, C. L. & Strugnell, R. A. (2015). Vaccination method affects immune response and bacterial growth but not protection in the salmonella typhimurium animal model of typhoid. Plos One, 10 (10), <https://doi.org/10.1371/journal.pone.0141356>.

Persistent Link:

<https://hdl.handle.net/11343/261750>

License:

[CC BY](#)

RESEARCH ARTICLE

Vaccination Method Affects Immune Response and Bacterial Growth but Not Protection in the *Salmonella* Typhimurium Animal Model of Typhoid

Clare L. Kinnear^{1,2*}, Richard A. Strugnell¹

1 Department of Microbiology and Immunology, The University of Melbourne, Melbourne, Victoria, Australia, **2** Department of Biosciences, The University of Melbourne, Melbourne, Victoria, Australia

* kinnear@unimelb.edu.au



OPEN ACCESS

Citation: Kinnear CL, Strugnell RA (2015) Vaccination Method Affects Immune Response and Bacterial Growth but Not Protection in the *Salmonella* Typhimurium Animal Model of Typhoid. PLoS ONE 10(10): e0141356. doi:10.1371/journal.pone.0141356

Editor: Ramon Arens, Leiden University Medical Center, NETHERLANDS

Received: July 25, 2015

Accepted: October 7, 2015

Published: October 28, 2015

Copyright: © 2015 Kinnear, Strugnell. This is an open access article distributed under the terms of the [Creative Commons Attribution License](https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Data Availability Statement: All raw data files are available from the Dryad database (doi:[10.5061/dryad.db2dd](https://doi.org/10.5061/dryad.db2dd)).

Funding: This work was supported by the National Health and Medical Research Council of Australia (<https://www.nhmrc.gov.au>), Project and Program Grants to R.A.S. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The authors have declared that no competing interests exist.

Abstract

Understanding immune responses elicited by vaccines, together with immune responses required for protection, is fundamental to designing effective vaccines and immunisation programs. This study examines the effects of the route of administration of a live attenuated vaccine on its interactions with, and stimulation of, the murine immune system as well as its ability to increase survival and provide protection from colonisation by a virulent challenge strain. We assess the effect of administration method using the murine model for typhoid, where animals are infected with *S. Typhimurium*. Mice were vaccinated either intravenously or orally with the same live attenuated *S. Typhimurium* strain and data were collected on vaccine strain growth, shedding and stimulation of antibodies and cytokines. Following vaccination, mice were challenged with a virulent strain of *S. Typhimurium* and the protection conferred by the different vaccination routes was measured in terms of challenge suppression and animal survival. The main difference in immune stimulation found in this study was the development of a secretory IgA response in orally-vaccinated mice, which was absent in IV vaccinated mice. While both strains showed similar protection in terms of challenge suppression in systemic organs (spleen and liver) as well as survival, they differed in terms of challenge suppression of virulent pathogens in gut-associated organs. This difference in gut colonisation presents important questions around the ability of vaccines to prevent shedding and transmission. These findings demonstrate that while protection conferred by two vaccines can appear to be the same, the mechanisms controlling the protection can differ and have important implications for infection dynamics within a population.

Introduction

Typhoid fever, caused by the bacterium *Salmonella enterica* serovar Typhi (*S. Typhi*) causes serious systemic disease in humans with an untreated case fatality rate of 10–20% [1]. The global burden of typhoid has been estimated at 21.7 million infections annually with 217,000 deaths [2]. While strategies for the control of typhoid are reliant primarily on improving

sanitation in developing countries, the use of antibiotics and vaccines is becoming more common [3]. Development of resistance to currently available antibiotics has led to a push for increased vaccine usage [4,5]. There are two vaccines currently on the market, first a live attenuated *S. Typhi* strain (Ty21a) that is administered orally, and secondly a Vi polysaccharide subunit vaccine administered parenterally. Both these vaccines are only partially effective with studies finding 16–96% efficacy at 3yrs post vaccination for orally administered vaccines and 55–72% at 1.4–3yrs for injectable vaccines [1,6–14].

Different routes of vaccine administration may result in differing stimulation of the immune system [15,16]. The consequences of any variation in immune response, not only on protection of the individual, but also on how this alters population dynamics such as transmission potential is important to understand in order to develop the most effective vaccine strategies.

The majority of studies on typhoid pathogenesis and immunology rely on mouse-models. *S. Typhi* is human specific and does not cause disease in mice, however recent development of humanised mice models are beginning to allow *S. Typhi* experiments in mice [17–20]. Despite this recent advancement, the majority of studies into typhoid use the closely related *Salmonella enterica* serovar Typhimurium (*S. Typhimurium*), which causes a typhoid-like systemic illness in mice. This system has been used extensively to identify appropriate live-attenuated strains for vaccine use [21–29], and to investigate the immune response required for both primary and secondary protection [30–40].

In order to understand the potential difference in the immune responses elicited by different vaccination methods, it is important to understand the natural route (oral) of infection, and how this differs when immunisation is performed intravenously or by other methods that bypass the gut.

Salmonella infection usually occurs through the ingestion of contaminated food or water. The bacteria travel through the gut to the lumen of the small intestine. Here the bacteria cross the epithelial barrier of the gut, either by active uptake by M-cells located predominantly in the Peyer's patches (PP) [41–45], or through enterocytes [46]. The bacteria then travel through the gut associated lymphoid tissue (GALT) to either the mesenteric lymph nodes (MLN), or directly to the bloodstream by uptake into macrophages, polymorphonuclear phagocytes (PMNs) and dendritic cells (DCs) [32]. Alternatively, bacteria may be engulfed by CX₃CR1^{hi} mononuclear phagocytes directly from the gut [47,48]. Once inside macrophages, PMNs and DCs, the bacteria travel to the spleen and liver where the bacteria multiply, forming multiple focal lesions which in extreme cases develop into granulomatous lesions [49]. Transmission of bacteria to new hosts results from large bacterial numbers in the caecum and colon, which are shed in the faeces. The method of colonisation of these organs is yet to be determined, with two alternative, or possibly concurrent, processes being the reseeded of the gut from bacterial populations in the gall bladder or mesenteric lymph nodes, or alternatively from resident populations established in the gut.

Other vaccination methods, which include intramuscular, intravenous and intraperitoneal, bypass all of the initial stages of infection and are delivered directly to the bloodstream [50]. This lack of interaction with the gut and its associated immune cells is likely to result in different stimulation of the immune system. To determine if these differences in the immune response are likely to have an effect on host responses to subsequent infections, an understanding of what components of the immune system are required for control and clearance of salmonella is required.

Low-virulence challenges with *S. Typhimurium* are controlled by the innate immune system (phagocytes and cytokines) [51], and subsequently cleared by CD4⁺ TCR- $\alpha\beta$ ⁺ T-cells [52]. However, virulent challenges require both early innate responses (macrophages and TNF- α ,

IL-12, IFN- γ and NK cells) and antibodies and T-cells, which must be primed by immunisation or previous exposure to a sub-lethal infection [53,54].

The role that T-cells and B-cells play in protection against virulent *Salmonella* challenges is still not fully understood, but both components are essential for effective protection. A series of studies using T-cell deficient mice reveal increased bacterial growth, chronic infections and increased host death [53,55]. This is also true of B-cells, where mice lacking B-cells (I μ ^{-/-}) show reduced survival to virulent challenge post-vaccination [34]. It is not just T-cells and B-cells in isolation that generate protection, but also the interactions between these components that are important. B-cells are important for effective activation of *Salmonella*-specific T-cells, as CD4⁺ T-cells from B-cell deficient mice have a reduced ability to produce Th-1 type cytokines [36,56]. The reverse is also true, with T-cell-deficient mice, which have impaired T-cell activation or lack proper T-cell/B-cell communication, produce little antibody despite functional B-cells [33,57]. Irrespective of the route taken in generating immunity through vaccination, it is generally believed that the key components required for effective control of secondary virulent salmonella infections are Th-1 type cytokines, specifically TNF- α , IFN- γ , and IL-12 and *Salmonella*-specific antibodies [31,38,58].

The aim of this study is to determine the effect that different vaccination methods have on immune stimulation and protection from secondary infection in the typhoid mouse model. We used an orally-administered live-attenuated vaccine and an intravenously (IV) administered live-attenuated vaccine. We have characterised the growth and clearance of the vaccine strain after both IV and oral vaccination, as well as shedding of the vaccine strain, systemic and mucosal antibody production, and cytokine serum levels. Further to this, we have determined the level of protection conveyed by each vaccination method, both in terms of growth suppression of the virulent challenge strain, and survival post challenge.

Materials and Methods

Ethics Statement

This study was carried out in strict accordance with the approval of The University of Melbourne Animal Ethics Committee (Permit number: 06222). All efforts were made to minimize animal suffering.

Mice

C57BL/6 mice were bred and housed at the University of Melbourne, Department of Microbiology and Immunology animal facility. All mice were aged 6–8 weeks. When necessary, mice were anaesthetised using Penthrane and euthanised by carbon dioxide (CO₂) asphyxiation.

Oral vaccination with *S. Typhimurium*

S. Typhimurium BRD509, an *aroA* deletion mutant of *S. Typhimurium* SL1344 [59], was used as the vaccine strain in all immunisation experiments. The bacterium was grown, without shaking at 37C for 24hrs in 500ml Luria Bertoni broth (LB) [60] containing 25 μ g/ml streptomycin. The flask was seeded with 10mls of an overnight culture of BRD509, taken from a glycerol stock. Bacteria from the 500ml culture were pelleted by centrifugation at 13,000 rpm for 15 minutes and resuspended in 800 μ l phosphate-buffered saline (PBS) to a concentration of approximately 10¹¹ cfu/ml. Inoculum counts were confirmed by dilution and plating on LB agar. Mice were administered 200 μ l (approximately 2 x 10¹⁰ bacteria) of the inoculum orally, under light anaesthesia, using a 4cm gastric gavage tube. Thirty minutes prior to immunisation,

100µl of 10% v/w sodium bicarbonate in distilled water was administered orally, in a similar manner, to neutralise stomach acidity.

IV Vaccination with *S. Typhimurium*

Oral vaccine inoculum was diluted to 10^3 cfu/ml in PBS and 200µl was administered using a 27 gauge needle into the tail vein.

Oral challenge with virulent *S. Typhimurium*

10ml LB (containing 25µg/ml streptomycin) was subcultured with 50µl of an overnight culture of *S. Typhimurium* SL1344 wildtype (wt) and was grown without shaking at 37°C for 24hrs. Bacteria were diluted in PBS to 5×10^7 cfu/ml. Bacterial counts were confirmed by plating on LB agar. Mice were challenged orally with 10^7 *S. Typhimurium* SL1344 wt in 200µl after pre-treatment with sodium bicarbonate.

Quantification of bacterial colonisation of organs

Mice were sacrificed at the indicated time points or when they were deemed moribund due to significant weight loss and acute physical signs of *Salmonella* infection. Organs (spleen, liver mesenteric lymph node (MLN) and Peyer's patches (PP)) were collected aseptically and placed in sterile plastic bags. 5ml PBS was added to each sample and samples were homogenised using a Stomacher 80. The number of viable bacteria were quantified by plating serial dilutions of tissue homogenates on LB agar containing streptomycin.

Bacterial loads—faeces

Mice were placed individually in clean cages with no bedding and 3–5 faecal pellets were collected in a 1.5ml tube. Pellets were weighed and diluted to 100mg/ml in PBS. Pellets were soaked for 1hr on ice then vortexed vigorously for 5mins. The number of viable bacteria per 100mg of faeces were quantified by plating serial dilutions of the faecal homogenate on XLD agar containing 25µg/ml streptomycin.

ELISA and cytokine sample collection—blood

Blood samples were collected in 1.5ml tubes from mice using tail bleeding. Serum was separated from blood cells by centrifugation at 6,500rpm for 10 minutes, the supernatant was transferred to a clean 1.5ml tube and recentrifuged at 6,500 rpm for 10 minutes. The supernatant was again removed to a clean 1.5ml tube and stored at -20°C until use.

ELISA sample collection—faeces

Faecal pellets were collected as outlined above and diluted to 100mg/ml in PBS containing 100µg/mL soybean trypsin inhibitor. Pellets were soaked for 1hr on ice, shaken vigorously for 5mins, then centrifuged for 15mins at 13,000rpm. The supernatant was removed to a fresh 1.5ml tube and the protease inhibitor phenyl methyl sulfonyl fluoride (PMSF) was added to a final concentration of 1mM. Samples were stored at -20°C until use.

ELISA

96-well plates were coated overnight at 4°C with 50µl/well *S. typhimurium* lipopolysaccharide (LPS) (10µg/ml) in PBS. Wells were emptied and blocked for a minimum of 1hr at 37°C with 100µl 1% BSA. Plates were then washed three times with PBS + 0.05% Tween-20 (PBST) and

serial dilutions of serum samples in PBST + 0.5% BSA were added to a total volume of 50µl/well. Plates were incubated overnight at 4°C or for 2hrs at 37°C. Plates were washed five times in PBST, then 50µl of HRP-conjugated anti-mouse IgA or IgG diluted 1/1000 in PBST + 0.5% BSA was added to each well and plates were incubated for 2hrs at 37°C or overnight at 4°C. After a final six washes with PBST the plates were developed using 50µl Immunopure o-Phenylenediamine (OPD) with H₂O₂ as the substrate. Following 10–15 minutes incubation in the dark, the reaction was stopped using 50µl 2N H₂SO₄ and the absorbance was read at 492nm. Endpoint titres were designated as the reciprocal of the dilution of specific antibody that gave an OD₄₉₂ of three times above the negative control reading.

To determine the titre of antibody subclasses in mouse sera, the same procedure as described above was used until the detection step, where 100µl of rat anti-mouse IgG1 or IgG2a specific antibody (diluted 1:1000 in PBST) was added to each well. ELISA plates were incubated with subclassing antibodies for 1 hour at 37°C. Unbound antibody was removed by washing plates 10 times in PBST. Bound subclassing reagents were then detected by adding 100µl of goat anti-rat antibody, conjugated to HRP (diluted 1/1000 in PBST), to each well and incubation at 37°C for 1 hour. Plates were then washed 10 times with PBST and developed as described above.

Cytokine CBA Assay

Cytokines, IL-12, IL-10, TNF-α and IFNγ were quantified using the BD Biosciences Cytometric Bead Array (CBA) Mouse Inflammation Kit with modifications as outlined below. Mouse Inflammation Capture Bead suspensions were used at 2µl / bead / test, made up to 50µl with assay diluent. 50µl of the bead suspension was added to 50µl of sample or standard together with 50µl of 1 in 6 dilution of PE Detection Reagents. Samples were incubated for 2 hours at room temperature in the dark then washed with 150µl of wash buffer and centrifuged at 200xg for 5 minutes. The supernatant was discarded and samples were resuspended in 80µl of wash buffer and analysed on a BD FACSCalibur.

Experimental Design

The effects of different vaccination techniques were examined in a series of three experiments (outlined below) that compared the performance of live *S. Typhimurium* oral and intravenous vaccines in their ability to colonise and elicit immune responses. A further two experiments were performed to assess the ability of these vaccination methods to provide protection from a virulent *S. Typhimurium* challenge.

Vaccine colonisation and clearance. Mice were vaccinated either orally (n = 26) or intravenously (n = 27) as described above. At days 7, 14, 28, 42 and 70 five or six mice were sacrificed from each group, and bacterial loads in the spleen, liver, mesenteric lymph nodes and Peyers' patches were quantified as described above.

Faecal shedding and antibody production. Mice were vaccinated either orally (n = 8) or intravenously (n = 7) as described above or left unvaccinated (n = 5). At days 0, 1, 3, 7 and then weekly until day 91, faecal samples were collected as outlined above for both faecal bacterial loads and for faecal IgA quantification by ELISA. On days 1, 7, 14, 21, 28, 42, 56, 70, 84 and 91 post vaccination, blood samples were collected as outlined above for serum IgG quantification by ELISA.

Cytokine production. Mice were vaccinated either orally (n = 5) or intravenously (n = 5) as described above or left unvaccinated (n = 5). At days 14 and 28 post vaccination, mice were tail bled as described above and serum samples were prepared for cytokine quantification using a CBA assay as described above.

Vaccine protection. Mice were vaccinated either orally ($n = 8$) or intravenously ($n = 9$) as described above or left unvaccinated ($n = 9$). At 10 weeks post vaccination all mice were challenged with a virulent strain of *S. Typhimurium* as outlined above. At day 5 post challenge, mice were sacrificed and bacterial loads in the spleen, liver, mesenteric lymph nodes and Peyer's patches were quantified as described above.

Survival. Mice were vaccinated either orally ($n = 14$) or intravenously ($n = 16$) as described above or left unvaccinated ($n = 11$). At 10 weeks post vaccination all mice were challenged with a virulent strain of *S. Typhimurium* as outlined above. Mice were monitored for signs of severe morbidity (greater than 15% weightloss combined with other acute signs of *Salmonella* infection including hunched posture and oily or ruffled fur) and sacrificed when determined to be moribund. Mice were monitored for 12 weeks post challenge and survival data was recorded for analysis.

Statistical Analysis

Bacterial counts and antibody reciprocal titres were log₁₀ transformed for normality. Where values were obtained as below the detection limit of the assay a value of half the detection limit was assigned. Bacterial counts from organs were analysed by ANOVA with Tukey HSD post-hoc comparisons performed when necessary. Where normal distributions could not be met due to large numbers of observations below detection limits of assays, non-parametric Van der Waerden tests were performed. IgG antibody responses and cytokine production were analysed using repeated-measures MANOVAs. For cytokine production, levels of cytokines in the serum of unvaccinated mice have been included in figures for comparisons but have not been included in statistical analysis. Statistical analyses were not performed on bacterial counts from faeces and faecal IgA antibody responses as the lack of variation (all values below the detection limit of the assay) in the intravenous vaccine group makes statistical analysis unnecessary and obvious differences can be determined visually. Survival analysis post challenge was performed using the Kaplan-Meier survival platform. Both survival analysis and vaccine protection experiments were performed twice. These data revealed no effect of experiment, and so the data were pooled for all analyses. All analyses were performed in JMP 8.0 (SAS Institute).

Results

Vaccine colonisation and clearance

The organ distribution of the vaccine strain BRD509 was determined after oral or intravenous inoculation. Intravenous and oral administration of the *S. Typhimurium* vaccine strain BRD509 resulted in similar patterns of vaccine growth and clearance over the vaccination period in the spleen, although intravenous administration resulted in 16- to 56-fold higher bacterial load through the peak of vaccine growth (full ANOVA results see [Table 1](#); [Fig 1C](#)). The growth and clearance from the liver shows a similar pattern to the spleen, but there is a significant interaction term between vaccination method and day post vaccination, most likely due to the similar bacterial counts between vaccination methods for days 7 as well as the more effective clearance of the IV administered vaccine late (day 28 to 70) (full ANOVA results see [Table 1](#); [Fig 1D](#)).

In contrast, analysis of vaccine growth in the gut-associated organs (mesenteric lymph nodes and Peyer's patches) showed very different patterns of colonisation and clearance based on the method of immunisation. While oral administration of the vaccine strain resulted in colonisation of the mesenteric lymph node (MLN) and Peyer's patches (PP), intravenous administration rarely resulted in bacteria in these tissues. In the MLN, oral vaccination led to high numbers of bacteria early in the infection, which drops over time, whereas IV vaccination

Table 1. ANOVA for vaccine colonisation and clearance.

	Spleen		Liver		MLN		PP	
	F-value	P-value	F-value	P-value	F-value	P-value	F-value	P-value
Full model ^a	38.234	<0.0001	61.726	<0.0001	20.085	<0.0001	28.655	<0.0001
Vaccination method ^b	15.077	0.0004	11.074	0.0018	74.070	<0.0001	112.904	<0.0001
Day post vaccination ^c	58.749	<0.0001	102.000	<0.0001	3.286	0.0195	12.397	<0.0001
Interaction (Vacc x Day) ^d	1.010	0.4127	4.980	0.0022	8.563	0.0001	16.755	0.0001

^a df_{between-groups} = 9, df_{within-groups} = 43

^b df_{between-groups} = 1, df_{within-groups} = 43

^c df_{between-groups} = 4, df_{within-groups} = 43

^d df_{between-groups} = 4, df_{within-groups} = 43

doi:10.1371/journal.pone.0141356.t001




Fig 1. Growth and clearance of the vaccine strain BRD509 following vaccination. Bacterial loads in the (A) Peyer's patches (PP), (B) mesenteric lymph nodes (MLN), (C) spleen and (D) liver of mice over 10 weeks following either oral vaccination with 10^{10} cfu *S. Typhimurium* BRD509 (black), or intravenous vaccination with 10^2 cfu *S. Typhimurium* BRD509 (grey) (n = 4–7 per group). Dashed grey and black lines represent the means for the IV and oral groups respectively. Boxplots display medians, IQRs and the complete spread of data. Dotted black lines represent the minimum detection limit of the assay (5 cfu). IV vaccination resulted in much higher levels of colonisation in the spleen and liver than oral vaccination, though was rarely detected in the Peyer's patches or mesenteric lymph nodes.

doi:10.1371/journal.pone.0141356.g001

required up to four weeks before bacteria were detected in the majority of mice, and even then only at very low levels (full ANOVA results see [Table 1](#); [Fig 1B](#)). This same pattern is seen in the PP (full ANOVA results see [Table 1](#); [Fig 1A](#)).

Faecal shedding

Oral administration of the vaccine strain resulted in faecal shedding of the vaccine strain for up to 5 weeks post vaccination. This was similar to the length of time where significant numbers of bacteria were present in the mesenteric lymph nodes and the Peyer's patches ([Fig 1](#)). Bacterial shedding of the vaccine strain was never observed after IV administration of the vaccine ([Fig 2](#)).

Antibody production

Both oral and intravenous vaccination resulted in the production of anti-*S. Typhimurium* LPS IgG antibodies. A repeated-measures MANOVA, incorporating both vaccine method and day post vaccination shows a significant effect of both vaccination method and day (Vacc method:




Fig 2. Bacterial shedding of the vaccine strain following oral and IV vaccination with *S. Typhimurium* BRD509. Bacterial loads in the faeces of mice where quantified on days 1, 3 and 7, then weekly for 12 weeks post vaccination with BRD509 either orally (black) or intravenously (grey). Dashed grey and black lines represent the means for the IV and oral groups respectively (n = 5 per group). Boxplots display medians, IQRs and the complete spread of data. Dotted black line represents minimum detection limit of the assay (5 cfu/100mg). Levels of bacteria in the faeces varied greatly between orally vaccinated individuals, but bacteria were generally not detected after 28 days post vaccination. No bacteria were detected in the faeces of IV vaccinated mice at any of the timepoints sampled.

doi:10.1371/journal.pone.0141356.g002




Fig 3. Levels of IgG, IgG1 and IgG2a in serum following IV or oral vaccination. (A) anti-LPS IgG antibody levels in the serum of mice vaccinated either orally (black) or intravenously (grey) with BRD509 from day 0 to day 91 post vaccination (n = 6–8 per group). Data are expressed as log₁₀ reciprocal titres. Dashed grey and black lines represent the means for the IV and oral groups respectively. Boxplots display medians, IQRs and the complete spread of data. Dotted black line represents the minimum detection limit for the assay (reciprocal titre of 50). **(B-E)** IgG subclassing. Levels of IgG1 and IgG2a in the serum at 21, 28, 56 and 91 days post vaccination either orally or intravenously. Graph represents pooled samples from five mice run in duplicate. Graphs represent mean ± standard error of the mean. There is no obvious quantitative difference between IgG1 and IgG2a levels for either vaccination method at any timepoint.

doi:10.1371/journal.pone.0141356.g003

$F_{(1,11)} = 8.24, p = 0.0152$; Day: $F_{(8,11)} = 174.90, p < 0.0001$; Int: $F_{(8,11)} = 5.09, p = 0.0666$; Fig 3A). The significant vaccination effect is also driven by the delayed antibody production in the intravenous vaccination group compared with the orally vaccinated group. Orally vaccinated mice mounted a *Salmonella*-specific IgG response more rapidly than IV vaccinated mice with significantly higher IgG levels in the serum of orally vaccinated mice at days 21 and 28 post vaccination (post-hoc d21: $F_{(1,11)} = 36.6465, p < 0.0001$; d28: $F_{(1,11)} = 13.0880, p = 0.0040$). By six weeks post vaccination, both methods elicited a comparable anti-LPS serum IgG antibody response (post-hoc d42: $F_{(1,11)} = 1.9895, p = 0.1860$), which is maintained over the remainder of the vaccination period. The early serum IgG response seen in the orally vaccinated mice was




Fig 4. Levels of IgA in the faeces following oral and IV vaccination. Anti-Salmonella LPS IgA antibody levels secreted in the faeces of mice vaccinated either orally (black) or intravenously (grey) from day 0 to day 91 post vaccination ($n = 7-8$ per group). Data are expressed as \log_{10} reciprocal titres. Dashed grey and black lines represent the means for the IV and oral groups respectively. Boxplots display medians, IQRs and the complete spread of data. Dotted line represents the minimum detection limit for the assay (reciprocal titre of 5). Faecal IgA was detected in all orally vaccinated mice by 21 days post vaccination, faecal IgA was never detected in IV vaccinated mice.

doi:10.1371/journal.pone.0141356.g004

the result of an increase in both IgG1 and IgG2a (Fig 3B). There is no obvious quantitative difference in IgG1 and IgG2a levels at any of the timepoints (Fig 3B–3E).

Secretory anti-Salmonella LPS IgA antibodies were detected as early as seven days post vaccination in some orally vaccinated mice and were detectable in all orally vaccinated mice by 21 days post vaccination. Faecal IgA was then maintained at a comparable level over the course of the vaccination period. Secretory anti-LPS IgA antibodies were never detected in IV vaccinated mice (Fig 4).

Cytokine production

IFN γ serum levels did not differ significantly between the two vaccination methods but were significantly reduced at 28 days post-vaccination compared with 14 days post-vaccination (Repeated-measures MANOVA: Vacc method: $F_{(1,7)} = 3.07$, $p = 0.1231$; Time: $F_{(1,7)} = 24.87$, $p = 0.0016$; Int: $F_{(1,7)} = 0.02$, $p = 0.8807$; Fig 5A). IL-10 and IL-12 were undetectable in the serum of the majority of mice at both 14 and 28 days post-vaccination (Fig 5B and 5D).

Analysis of TNF- α levels revealed a significant vaccination method and day post vaccination interaction effect ($F_{(1,7)} = 7.59$, $p = 0.0283$), with no main effects (Repeated-measures




Fig 5. Cytokine levels in the serum of IV vaccinated, orally vaccinated and unvaccinated mice. Cytokine serum levels (pg/ml) at 14 and 28 days post oral (□), intravenous (△) or no (○) vaccination. IL-10 and IL-12 were undetectable in almost all mice. An increase in production of IFN-γ and TNF-α was seen in both IV and orally vaccinated mice. For IFN-γ there was no difference between the two vaccination methods. Orally vaccinated mice showed an increase of TNF-α at day 14 which subsequently decreased by day 28. Only some IV vaccinated mice had detectable TNF-α levels at day 14, but TNF-α was detectable in the serum of all IV vaccinated mice at day 28.

doi:10.1371/journal.pone.0141356.g005

MANOVA: Vacc method: $F_{(1,7)} = 0.36$, $p = 0.5688$; Day: $F_{(1,7)} = 1.70$, $p = 0.2332$). Mice vaccinated orally show the highest level of TNF- α at day 14 and then a large reduction in TNF- α by day 28. In mice vaccinated intravenously, TNF- α was only detected in two of five mice at day 14 and in all mice at day 28 but still only at low levels compared to the peak at day 14 for orally vaccinated mice (Fig 5C). From this experiment it is not possible to say if oral vaccination stimulates a greater TNF- α response, as it is possible that a peak in TNF- α levels may just be delayed in IV vaccinated mice and hence not detected in this experiment.

Vaccine protection

Oral and intravenous vaccination led to equal suppression of SL1344 growth in the spleen and liver following challenge with this virulent wild-type *S. Typhimurium* (Spleen: $F_{(2, 23)} = 31.41$, $p < 0.0001$; Liver: $F_{(2, 23)} = 23.51$, $p < 0.0001$; for post-hoc analysis see Fig 6C & 6D). In the gut associated organs (MLN and PP), there is also an overall vaccination effect (Van der Waerden: MLN: $\chi^2 = 16.58$, $df = 2$, $p = 0.0003$; PP: $\chi^2 = 11.75$, $df = 2$, $p = 0.0028$; Fig 6C and 6D). Oral vaccination resulted in reduced colonisation following a virulent challenge, but unlike in the




Fig 6. Reduction in colonisation by a virulent pathogen following IV, oral or no vaccination. Bacterial loads in the (A) PP, (B) MLN, (C) spleen and (D) liver at day 5 post challenge with a virulent strain following oral (black), intravenous (grey) or no (striped) vaccination (n = 8–9 per group). Dotted line represents the minimum detection limit for the assay (5 cfu / organ). Boxplots display medians, IQRs and the complete spread of data. Data are representative of two experiments. In the spleen and liver both oral and IV vaccination resulted in significant reduction in colonisation by SL1344, with no significant difference between the vaccination methods. In the mesenteric lymph nodes and Peyer’s patches however, oral vaccination resulted in a significant reduction in colonisation by SL1344 but IV vaccination did not. Bars indicate significant difference between groups following unplanned post-hoc t-tests.

doi:10.1371/journal.pone.0141356.g006

systemic organs, IV vaccination did not lead to a significant reduction in colonisation of these organs compared to unvaccinated mice (for post-hoc analysis see Fig 6A and 6B).

Survival

Both methods of vaccination resulted in an increased survival following challenge with virulent *S. Typhimurium* compared with unvaccinated mice. There was no significant difference in the survival times of mice vaccinated either intravenously (25% survival), or orally (44% survival) over a 12-week period, post virulent challenge (IV/oral survival: Wilcoxon: $\chi^2 = 1.21$, $df = 1$, $p = 0.2709$; Log-Rank: $\chi^2 = 1.25$, $df = 1$, $p = 0.2637$; Fig 7).

Discussion

Comparative studies of immune responses to vaccines predominantly focus on differences in the vaccine strains [27–29,61,62], or the effectiveness of adjuvants or specific antigens [63,64], with only a handful providing any insight into the more simple modifications like method of delivery [65–67]. This study demonstrates that administering the same vaccine via different routes can result in significant differences in immune stimulation. In the murine typhoid model, these differences did not impact survival from secondary infections.




Fig 7. Survival of mice given a virulent challenge following IV, oral or no vaccination. Mice were either orally vaccinated with 10^{10} BRD509 (\square) or IV vaccinated with 10^2 BRD509 (\triangle) 10 weeks prior to challenge or unvaccinated (\circ). Data are representative of two experiments. Both IV and oral vaccination increased the survival of mice compared to the unvaccinated group. There was no significant difference in survival between orally and IV vaccinated mice.

doi:10.1371/journal.pone.0141356.g007

The most obvious difference in immune response detected in this study is in the induction of specific secretory IgA (SIgA) in orally, but not IV vaccinated mice. These results indicate that early gut interactions are important for production of secretory IgA. IV vaccinated mice that have minimal to no bacterial colonisation of the PP and MLN, also fail to generate a detectable secretory IgA response. This is consistent with studies showing that colonisation of the PP is required for the induction of a SIgA response [65].

The differences between vaccination methods in immune stimulation are also reflected in the outcome of a secondary challenge with a virulent strain. Our data shows that oral vaccination resulted in a significant reduction in colonisation in gut-associated organs from a secondary challenge compared with IV vaccinated mice. In IV-vaccinated mice, the colonisation levels in these organs are comparable to unvaccinated mice. This effect might be due to SIgA as previous studies have shown that mice that have no secretory antibody response (pIgR^{-/-}) are more susceptible to infections with virulent strains [68], and also that infections with *Salmonella* strains that are unable to be bound by SIgA result in higher levels of colonisation in systemic organs than SIgA sensitive strains [69]. However, in a study by Uren *et al.*, immunised pIgR^{-/-} mice show similar protection against secondary colonisation of the gut-associated organs as C57BL/6 mice, indicating that it is not SIgA alone that is responsible for the reduced gut colonisation [70].

Another interesting difference in immune stimulation between the two vaccination methods is the delay in development of a serum IgG response in IV vaccinated mice compared with orally vaccinated mice. Surprisingly, the higher levels of colonisation in the systemic organs in IV vaccinated mice by the vaccine strain did not result in greater induction of specific antibody. Instead, interactions of orally administered bacteria with the immune system in the gut-associated organs and GALT (gut-associate lymphoid tissue), as occurs during oral vaccination, appears to lead to more rapid development of serum antibodies, with peak serum IgG levels reached up to 4 weeks faster (in half the time) by oral vaccination.

Despite the differences discussed in immune stimulation and protection from colonisation of the gut-associated organs, there is no difference in survival of mice challenged with a virulent strain following IV or oral vaccination. This lack of difference in survival is also reflected in the similar levels of protection from colonisation by secondary infection in the systemic organs (spleen and liver). While oral vaccination can prevent colonisation of systemic organs [69], our data show that it is not essential for preventing systemic colonisation and doesn't increase survival.

We have highlighted the differences in immune response between our vaccination methods, but the lack of difference in protection in systemic organs and overall survival most likely results from the many similarities in immune response between the two groups. Firstly there is no significant difference in stimulation of the cytokines INF γ , IL-10, IL-12 and TNF α , which are deemed essential for control of secondary infections [31,38,58]. Despite the delay in serum IgG stimulation in IV vaccinated mice, again there is no difference in serum IgG titres between the vaccination methods at the time of challenge. These data indicate that while oral vaccination had significant implications for early control and secondary colonisation of the gut-associate organs, both vaccination methods were equally capable of generating an immune response to control systemic infection and protect the vaccinated individual.

While both vaccination methods provide comparable protection for the vaccinated individual in murine typhoid, the difference in the ability of both the vaccination strain and the secondary challenge strains to colonise the gut in IV and orally vaccinated mice has significant implications for the health of others in the population. First, the colonisation of the gut and the resulting shedding of the vaccine strain from orally vaccinated mice increases the potential for transmission of the vaccine strain to other individuals in areas with poor sanitation. This may

be either a positive, as it helps to generate immunity in the population as a whole, or a negative, as it puts immunocompromised individuals at serious risk. As the infectious dose required to transmit the vaccine strain is significantly higher than the level of shedding we see here (Fig 2), it seems unlikely that transmission would be a significant issue.

The local response elicited by oral but not IV vaccination prevents bacteria from colonising not only the PP and MLN but also the small intestine and the colon (see S1 Fig). As bacteria travel out of the colon in the faeces, bacterial numbers in the colon are likely a proxy for the number of bacteria being shed and the risk of transmission from that individual. While orally vaccinated mice have a minimal chance of transmitting secondary infections, as they have almost no detectable bacteria in the gut, IV vaccination provides no reduction in gut colonisation from a secondary infection. This means that while IV vaccinated individuals gain reasonable protection against disease, they are just as likely as unvaccinated individuals to transmit a virulent pathogen.

Our data highlight that while two vaccines may be equally capable of controlling an infection and protecting vaccinated individuals from disease, this does not mean that they are of equal merit for use as control mechanisms in populations. Here, our two vaccination methods have the potential to result in significant differences in the spread of pathogens between individuals in a population. The implications of these differences for infection dynamics are unknown and vital for predicting population wide implications of vaccine strategies.

Supporting Information

S1 Fig. Reduction in colonisation by a virulent pathogen (SL1344) following IV, oral or no vaccination in the gut. Bacterial loads in the contents of the a) small intestines and b) colon at 48hrs post challenge with a virulent strain following oral (black), intravenous (grey) or no (striped) vaccination (n = 4 per group). Data are represented as means + standard error of the mean. Dotted line represents the minimum detection limit for the assay (5cfu / organ). (TIFF)

Acknowledgments

We thank J. Holden for his practical assistance and M.A. Elgar and two reviewers for their comments on the manuscript.

Author Contributions

Conceived and designed the experiments: CLK RAS. Performed the experiments: CLK. Analyzed the data: CLK. Wrote the paper: CLK RAS.

References

1. WHO (2008) Typhoid vaccines: WHO position paper. *Weekly Epidemiological Record* 83: 49–59. PMID: [18260212](#)
2. Crump JA, Luby SP, Mintz ED (2004) The global burden of typhoid fever. *Bulletin of the World Health Organization* 82: 346–353. PMID: [15298225](#)
3. Crump JA, Mintz ED (2010) Global trends in typhoid and paratyphoid fever. *Emerging Infections* 50: 241–246.
4. Asna S, Haq JA, Rahman M (2003) Nalidixic acid-resistant *Salmonella enterica* serovar typhi with decreased susceptibility to ciprofloxacin caused treatment failure: A report from Bangladesh. *Jpn J Infect Dis* 56: 32–33. PMID: [12711825](#)
5. Capoor MR, Nair D (2010) Quinolone and cephalosporin resistance in enteric Fever. *Journal of global infectious diseases* 2: 258–262. doi: [10.4103/0974-777X.68529](#) PMID: [20927288](#)

6. Wahdan MH, Serie C, Cerisier Y, Sallam S, Germanier R (1982) A controlled field trial of live *Salmonella typhi* strain Ty21a oral vaccine against typhoid—3-year results. *J Infect Dis* 145: 292–295.
7. Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R (1989) Progress in vaccines against typhoid fever. *Reviews of Infectious Diseases* 11: S552–S567. PMID: [2669099](#)
8. Levine MM, Ferreccio C, Cryz S, Ortiz E (1990) Comparison of enteric-coated capsules and liquid formulation of Ty21a typhoid vaccine in randomized controlled field trial *Lancet* 336: 891–894. PMID: [1976928](#)
9. Acharya IL, Lowe CU, Thapa R, Gurubacharya VL, Shrestha MB, Cadoz M, et al. (1987) Prevention of typhoid-fever in Nepal with the Vi capsular polysaccharide of salmonella-typhi—A preliminary report. *New England Journal of Medicine* 317: 1101–1104. PMID: [3657877](#)
10. Klugman KP, Koornhof HJ, Schneerson R, Cadoz M, Gilbertson IT, Robbins JB, et al. (1987) Protective activity of Vi-capsular polysaccharide vaccine against typhoid fever. *Lancet* 2: 1165–1169. PMID: [2890805](#)
11. Klugman KP, Koornhof HJ, Robbins JB, LeCam NN (1996) Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. *Vaccine* 14: 435–438. PMID: [8735556](#)
12. Engels EA, Falagas ME, Lau J, Bennish ML (1998) Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxicity. *Br Med J* 316: 110–115.
13. Black RE, Levine MM, Ferreccio C, Clements ML, Lanata C, Rooney J, et al. (1990) Efficacy of one or 2 doses of Ty21a *Salmonella-typhi* vaccine in enteric-coated capsules in a controlled field trial *Vaccine* 8: 81–84.
14. Simanjuntak CH, Paleologo FP, Punjabi NH, Darmowigoto R, Totosudirjo SH, Haryanto P, et al. (1991) Oral immunization against typhoid-fever in Indonesia with Ty21a vaccine. *Lancet* 338: 1055–1059. PMID: [1681365](#)
15. Hu H, Huang XQ, Tao L, Huang Y, Cui BA, Wang HZ (2009) Comparative analysis of the immunogenicity of SARS-CoV nucleocapsid DNA vaccine administered with different routes in mouse model. *Vaccine* 27: 1758–1763. doi: [10.1016/j.vaccine.2009.01.021](#) PMID: [19186202](#)
16. Kantele A, Pakkanen SH, Karttunen R, Kantele JM (2013) Head-to-Head Comparison of Humoral Immune Responses to Vi Capsular Polysaccharide and Salmonella Typhi Ty21a Typhoid Vaccines-A Randomized Trial. *Plos One* 8. doi: [10.1371/journal.pone.0082806](#) PMID: [24482673](#)
17. Song JM, Willinger T, Rongvaux A, Eynon EE, Stevens S, Manz MG, et al. (2010) A Mouse Model for the Human Pathogen Salmonella Typhi. *Cell Host Microbe* 8: 369–376. doi: [10.1016/j.chom.2010.09.003](#) PMID: [20951970](#)
18. Mian MF, Pek EA, Chenoweth MJ, Ashkar AA (2011) Humanized mice are susceptible to Salmonella typhi infection. *Cell Mol Immunol* 8: 83–87. doi: [10.1038/cmi.2010.52](#) PMID: [21200387](#)
19. Fang FC, Baumler AJ (2012) A Tollgate for Typhoid. *Cell* 151: 473–475. doi: [10.1016/j.cell.2012.10.016](#) PMID: [23101620](#)
20. Mathur R, Oh H, Zhang DK, Park SG, Seo J, Koblansky A, et al. (2012) A Mouse Model of Salmonella Typhi Infection. *Cell* 151: 590–602. doi: [10.1016/j.cell.2012.08.042](#) PMID: [23101627](#)
21. Hoiseh SK, Stocker BAD (1981) Aromatic-dependent *Salmonella typhimurium* are non-virulent and effective as live vaccines. *Nature* 291: 238–239. PMID: [7015147](#)
22. Curtiss R, Goldschmidt RM, Fletchall NB, Kelly SM (1988) Avirulent *Salmonella typhimurium* delta-cya delta-crp oral vaccine strains expressing a streptococcal colonization and virulence antigen. *Vaccine* 6: 155–160. PMID: [3291452](#)
23. Miller SI, Loomis WP, Alpuhearanda C, Behlau I, Hohmann E (1993) The PhoP virulence regulon and live oral salmonella vaccines *Vaccine* 11: 122–125. PMID: [8438611](#)
24. Strahan K, Chatfield SN, Tite J, Dougan G, Hormaeche CE (1992) Impaired resistance to infection does not increase the virulence of salmonella htra live vaccines for mice *Microbial Pathogenesis* 12: 311–317. PMID: [1630300](#)
25. Tacket CO, Hone DM, Curtiss R, Kelly SM, Losonsky G, Guers L, et al. (1992) Comparison of the safety and immunogenicity of delta-aroC delta-aroD and delta-cya delta-crp *Salmonella typhi* strains in adult volunteers. *Infection and Immunity* 60: 536–541. PMID: [1730487](#)
26. Tacket CO, Hone DM, Losonsky GA, Guers L, Edelman R, Levine MM (1992) Clinical acceptability and immunogenicity of cvd 908 *Salmonella typhi* vaccine strain. *Vaccine* 10: 443–446. PMID: [1609547](#)
27. Tacket CO, Szein MB, Losonsky GA, Wasserman SS, Nataro JP, Edelman R, et al. (1997) Safety of live oral Salmonella typhi vaccine strains with deletions in htrA and aroC aroD and immune response in humans. *Infection and Immunity* 65: 452–456. PMID: [9009296](#)

28. Lowe DC, Savidge TC, Pickard D, Eckmann L, Kagnoff MF, Dougan G, et al. (1999) Characterization of candidate live oral *Salmonella typhi* vaccine strains harboring defined mutations in *aroA*, *aroC*, and *htrA*. *Infection and Immunity* 67: 700–707. PMID: [9916080](#)
29. Hohmann EL, Oletta CA, Killeen KP, Miller SI (1996) *phoP/phoQ*-deleted *Salmonella typhi* (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. *J Infect Dis* 173: 1408–1414. PMID: [8648213](#)
30. Everest P, Allen J, Papakonstantinou A, Mastroeni P, Roberts M, Dougan G, (1997) *Salmonella typhimurium* infections in mice deficient in interleukin-4 production—Role of IL-4 in infection-associated pathology. *Journal of Immunology* 159: 1820–1827.
31. Everest P, Roberts M, Dougan G (1998) Susceptibility to *Salmonella typhimurium* infection and effectiveness of vaccination in mice deficient in the tumor necrosis factor alpha p55 receptor. *Infection and Immunity* 66: 3355–3364. PMID: [9632605](#)
32. Vazquez-Torres A, Jones-Carson J, Baumler AJ, Falkow S, Valdivia R, Brown W, et al. (1999) Extraintestinal dissemination of *Salmonella* by CD18-expressing phagocytes. *Nature* 401: 804–808. PMID: [10548107](#)
33. Mittrucker HW, Kohler A, Mak TW, Kaufmann SHE (1999) Critical role of CD28 in protective immunity against *Salmonella typhimurium*. *Journal of Immunology* 163: 6769–6776.
34. Mittrucker HW, Raupach B, Kohler A, Kaufmann SHE (2000) Cutting edge: Role of B lymphocytes in protective immunity against *Salmonella typhimurium* infection. *Journal of Immunology* 164: 1648–1652.
35. Netea MG, Fantuzzi G, Kullberg BJ, Stuyt RJL, Pulido EJ, McIntyre RC, et al. (2000) Neutralization of IL-18 reduces neutrophil tissue accumulation and protects mice against lethal *Escherichia coli* and *Salmonella typhimurium* endotoxemia. *Journal of Immunology* 164: 2644–2649.
36. Mastroeni P, Simmons C, Fowler R, Hormaeche CE, Dougan G (2000) *Igh-6(-/-)* (B-cell-deficient) mice fail to mount solid acquired resistance to oral challenge with virulent *Salmonella enterica* serovar typhimurium and show impaired Th1 T-cell responses to *Salmonella* antigens. *Infection and Immunity* 68: 46–53. PMID: [10603367](#)
37. Monack DM, Hersh D, Ghori N, Bouley D, Zychlinsky A, Falkow S, (2000) *Salmonella* exploits caspase-1 to colonize Peyer's patches in a murine typhoid model. *Journal of Experimental Medicine* 192: 249–258. PMID: [10899911](#)
38. Price JD, Simpfendorfer KR, Mantena RR, Holden J, Heath WR, van Rooijen N, et al. (2007) Gamma interferon-independent effects of interleukin-12 on immunity to *Salmonella enterica* serovar typhimurium. *Infection and Immunity* 75: 5753–5762. PMID: [17875635](#)
39. Uren T, Wijburg OLC, Johansen FE, Koentgen F, Brandtzaeg P, Strugnell RA, (1999) The role of mucosal antibodies in vaccine-mediated protection against *Salmonella typhimurium*. *Immunology Letters* 69: 154–155.
40. Kupz A, Scott TA, Belz GT, Andrews DM, Greyer M, Lew AM, et al. (2013) Contribution of Thy1(+) NK cells to protective IFN-gamma production during *Salmonella Typhimurium* infections. *Proceedings of the National Academy of Sciences of the United States of America* 110: 2252–2257. doi: [10.1073/pnas.1222047110](#) PMID: [23345426](#)
41. Carter PB, Collins FM (1974) Route of enteric infection in normal mice. *Journal of Experimental Medicine* 139: 1189–1203. PMID: [4596512](#)
42. Jones BD, Ghori N, Falkow S (1994) *Salmonella typhimurium* initiates murine infection by penetrating and destroying the specialized epithelial M-cells of the Peyer's-patches *Journal of Experimental Medicine* 180: 15–23. PMID: [8006579](#)
43. Jensen VB, Harty JT, Jones BD (1998) Interactions of the invasive pathogens *Salmonella typhimurium*, *Listeria monocytogenes*, and *Shigella flexneri* with M cells and murine Peyer's patches. *Infection and Immunity* 66: 3758–3766. PMID: [9673259](#)
44. Jepson MA, Clark MA (2001) The role of M cells in *Salmonella* infection. *Microbes and Infection* 3: 1183–1190. PMID: [11755406](#)
45. Halle S, Bumann D, Herbrand H, Willer Y, Dahne S, Forster R, et al. (2007) Solitary intestinal lymphoid tissue provides a productive port of entry for *Salmonella enterica* serovar typhimurium. *Infection and Immunity* 75: 1577–1585. PMID: [17283101](#)
46. van Asten A, Koninkx J, van Dijk JE (2005) *Salmonella* entry: M cells versus absorptive enterocytes. *Veterinary Microbiology* 108: 149–152. PMID: [15885932](#)
47. Diehl GE, Longman RS, Zhang JX, Breart B, Galan C, Cuesta A, et al. (2013) Microbiota restricts trafficking of bacteria to mesenteric lymph nodes by CX(3)CR1(hi) cells. *Nature* 494: 116–120. doi: [10.1038/nature11809](#) PMID: [23334413](#)

48. Niess JH, Brand S, Gu XB, Landsman L, Jung S, McCormick BA, et al. (2005) CX(3)CR1-mediated dendritic cell access to the intestinal lumen and bacterial clearance. *Science* 307: 254–258. PMID: [15653504](#)
49. Nakoneczna I, Hsu HS (1980) The comparative histopathology of primary and secondary lesions in murine salmonellosis *British Journal of Experimental Pathology* 61: 76–84. PMID: [6990953](#)
50. Mastroeni P, Grant AJ (2011) Spread of *Salmonella enterica* in the body during systemic infection: unravelling host and pathogen determinants. *Expert Reviews in Molecular Medicine* 13: e12. doi: [10.1017/S1462399411001840](#) PMID: [21477411](#)
51. Mastroeni P, Harrison JA, Robinson JH, Clare S, Khan S, Maskell DJ, et al. (1998) Interleukin-12 is required for control of the growth of attenuated aromatic- compound-dependent salmonellae in BALB/c mice: Role of gamma interferon and macrophage activation. *Infection and Immunity* 66: 4767–4776. PMID: [9746577](#)
52. Hess J, Ladel C, Miko D, Kaufmann SHE (1996) *Salmonella typhimurium* aroA(-) infection in gene-targeted immunodeficient mice—Major role of CD4(+) TCR-alpha beta cells and IFN-gamma in bacterial clearance independent of intracellular location. *Journal of Immunology* 156: 3321–3326.
53. Mastroeni P, Villarrealramos B, Hormaeche CE (1992) Role of T-cells, TNF-alpha and IFN-gamma in recall of immunity to oral challenge with virulent salmonellae in mice vaccinated with live attenuated aro- salmonella vaccines. *Microbial Pathogenesis* 13: 477–491. PMID: [1363824](#)
54. Mastroeni P, Villarrealramos B, Hormaeche CE (1993) Adoptive transfer of immunity to oral challenge with virulent salmonellae in innately susceptible Balb/C mice requires both immune serum and T-cells. *Infection and Immunity* 61: 3981–3984. PMID: [8359920](#)
55. Nauciel C (1990) Role of CD4+ T-cells and T-independent mechanisms in acquired-resistance to *Salmonella typhimurium* infection *Journal of Immunology* 145: 1265–1269.
56. Ugrinovic S, Menager N, Goh N, Mastroeni P (2003) Characterization and development of T-cell immune responses in B-cell-deficient (Igh-6(-/-)) mice with *Salmonella enterica* serovar Typhimurium infection. *Infection and Immunity* 71: 6808–6819. PMID: [14638767](#)
57. Sinha K, Mastroeni P, Harrison J, deHormaeche RD, Hormaeche CE (1997) *Salmonella typhimurium* aroA, htrA, and aroD htrA mutants cause progressive infections in athymic (nu/nu) BALB/c mice. *Infection and Immunity* 65: 1566–1569. PMID: [9119506](#)
58. Griffin AJ, McSorley SJ (2011) Development of protective immunity to *Salmonella*, a mucosal pathogen with a systemic agenda. *Mucosal Immunol* 4: 371–382. doi: [10.1038/mi.2011.2](#) PMID: [21307847](#)
59. Strugnell R, Dougan G, Chatfield S, Charles I, Fairweather N, Tite J, et al. (1992) Characterization of a *Salmonella typhimurium* aro vaccine strain expressing the p.69 antigen of *Bordetella pertussis*. *Infection and Immunity* 60: 3994–4002.
60. Sambrook J, Fritsch EF, Maniatis T (1989) *Molecular Cloning: A Laboratory Manual*. Cold Spring Harbour, N.Y.: Cold Spring Harbor Laboratory Press.
61. Zheng SY, Yu B, Zhang K, Chen M, Hua YH, Yuan S, et al. (2012) Comparative immunological evaluation of recombinant *Salmonella Typhimurium* strains expressing model antigens as live oral vaccines. *BMC Immunol* 13.
62. Zhang X, Kelly SM, Bollen W, Curtiss R (1999) Protection and immune responses induced by attenuated *Salmonella typhimurium* UK-1 strains. *Microbial Pathogenesis* 26: 121–130. PMID: [10089152](#)
63. Kaur J, Jain SK (2013) Protection against experimental salmonellosis by recombinant 49 kDa OMP of *Salmonella enterica* serovar Typhi: biochemical aspects. *Biologia* 68: 194–201.
64. Rueckert C, Guzman CA (2012) *Vaccines: From Empirical Development to Rational Design*. PLoS Pathogens 8.
65. Martinoli C, Chiavelli A, Rescigno M (2007) Entry route of *Salmonella typhimurium* directs the type of induced immune response. *Immunity* 27: 975–984. PMID: [18083577](#)
66. Harrison JA, VillarrealRamos B, Mastroeni P, DeHormaeche RD, Hormaeche CE (1997) Correlates of protection induced by live Aro(-) *Salmonella typhimurium* vaccines in the murine typhoid model. *Immunology* 90: 618–625. PMID: [9176117](#)
67. Uddin AN, Bejugam NK, Gayakwad SG, Akther P, D'Souza MJ (2009) Oral delivery of gastro-resistant microencapsulated typhoid vaccine. *Journal of Drug Targeting* 17: 553–560. doi: [10.1080/10611860903067301](#) PMID: [19563303](#)
68. Wijburg OLC, Uren TK, Simpfendorfer K, Johansen FE, Brandtzaeg P, Strugnell RA (2006) Innate secretory antibodies protect against natural *Salmonella typhimurium* infection. *Journal of Experimental Medicine* 203: 21–26. PMID: [16390940](#)
69. Michetti P, Mahan MJ, Slauch JM, Mekalanos JJ, Neutra MR (1992) Monoclonal secretory immunoglobulin-A protects mice against oral challenge with the invasive pathogen *Salmonella typhimurium* *Infection and Immunity* 60: 1786–1792. PMID: [1373399](#)

70. Uren TK, Wijburg OLC, Simmons C, Johansen FE, Brandtzaeg P, Strugnell RA (2005) Vaccine-induced protection against gastrointestinal bacterial infections in the absence of secretory antibodies. *European Journal of Immunology* 35: 180–188. PMID: [15593123](#)